Ranbaxy Laboratories said Norwegian court ruled in its favor against Pfizer Inc

Generic drugmaker Ranbaxy Laboratories on Tuesday said a Norwegian court ruled in its favor against Pfizer Inc. involving two patents on a cholesterol-lowering drug. The Oslo city court found that Ranbaxy's Atorvastatin was not infringing Pfizer's Norwegian patents, Ranbaxy said in a statement.